|
Ananda Pharma PLC on Tuesday said the first subject has been dosed in the phase 1 pharmacokinetic study for its lead cannabidiol drug candidate, MRX1. Ananda is a London-based biopharmaceutical company that develops regulatory-approved cannabinoid medicines to treat complex, chronic conditions. The pharmacokinetic study of MRX1 is taking place at the clinical site in Melbourne, Australia, and initial results are anticipated in the first quarter of 2026. MRX1 is already advancing into phase 2 clinical trials in endometriosis and chemotherapy-induced peripheral neuropathy, said the company. The new study will run independently of the ongoing phase 2 trials and are designed to characterise systemic exposure and support future dose optimisation. This first in-human study will deliver ‘critical’ data for future clinical development, as well as support regulatory submissions to the US Food & Drug Administration, the European Medicines Agency and the UK’s Medicines & Healthcare Products Regulatory Agency. ‘We are delighted to have dosed the first participant in our Phase 1 trial using MRX1. This study is a strategic addition to the MRX1 program and sees us move from formulation development into full clinical execution,’ said Chief Executive Officer Melissa Sturgess. ‘Importantly, it brings us one step closer to delivering a placebo controlled clinical trial tested, regulatory approved CBD medicine for women suffering from endometriosis and people struggling with chemotherapy induced peripheral neuropathy to market.’ Shares in Ananda Pharma were flat at 0.31 pence on the Aquis Exchange on Tuesday afternoon. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
